Early CAR-T Results for CD33 Positive AML Using PRGN-3006 Ultracar-T | David Sallman | ASH 2021 #AML Published 2021-12-13 Download video MP4 360p Download video MP4 720p Recommendations 47:56 AML diagnosis and treatment 2022 09:58 CMML/JMML 18:46 Approach to the Exam for Parkinson's Disease 50:27 Reduce dementia risk 06:31 What is the goal of treatment? Manage symptoms or cure MDS? #MDS 05:36 CD33 and Alzheimer's Disease 11:30 Who is a Good Candidate for PRRT (Peptide Receptor Radionuclide Therapy) with Jonathan Strosberg, MD 03:26 CLL Diagnosis - The Top 5 Things You Need to Know | #CLL 02:46 An update on emerging therapies for the treatment of polycythemia vera 19:43 Frank Fiorenini's Aortic Hope Survivor Series Video 14:46 Excess Deaths at Night - Obstructive Sleep Apnea Explained Clearly 18:40 Matthew Perry's Death From Ketamine Explained (Is It Safe For You?) 04:01 AVL: Vanadium Series Part 2 - Vanadium Flow Batteries 27:35 Clarifying the Confusing Truth About Depression and Borderline Personality Disorder (BPD) 02:27 What is a Serum Protein Electrophoresis (SPEP)? 02:50 What is watch and wait? Why would I wait to treat my MDS? #MDS 13:32 Overview of Actinium’s CD33 Program; Actimab A 225Ac Lintuzumab 02:38 Local doctor says coconut oil helps reduce symptoms of Alzheimer's disease 14:10 All about Mitochondrial disease| Vlogmas 2021 14:38 Cognitive impairment in schizophrenia Similar videos 01:20 PRGN-3006 in the treatment of AML and MDS 02:05 Phase I results of rapidly manufactured Prgn-3006 Ultracar-T in R/R acute myeloid leukemia 02:38 DARIC33 CAR T-cells in AML 1:31:25 CAR T Cell Therapy in MDS/AML 01:53 First-in-human trial of rapidly manufactured UltraCAR T-cells in R/R myeloid malignancies 02:23 An update on CAR-T therapy in AML: challenges & emerging strategies 00:49 Gilteritinib and CAR T-cell therapy in high-risk pediatric leukemias 09:22 What is CAR-T Cell Therapy? 01:05 T-cell evolution in AML and its impact on the efficacy of bispecific antibodies 02:23 AMG 673: novel half-life extended anti-CD33/CD3 BiTE in R/R AML 04:46 How can we improve efficacy of CAR T-cell therapy in AML? 01:42 Novel treatment combinations in AML: what’s to come? 49:11 UltraCAR-T Therapy – Scope & Possibilities in Multiple Myeloma Management 05:40 Current concepts and future developments in T-cell-based immunotherapy of AML 01:01 Novel treatment paradigms for AML at ASH 2021 02:24 Menin Inhibitors are on the Horizon for NPM1 Mutated AML | Eytan Stein | ASH 2021 #AML 02:11 FLT3-mutated AML data at ASH 2021 03:14 Determining the optimal frontline treatment of AML 02:04 Linking poor cytogenetics and outcomes in MDS More results